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ABSTRACT
Background: we depict the experience with the use of thrombolysis for acute ischemic stroke in a tertiary center in South America. 
Objective: to describe the main outcomes in our population of patients aged less and older than 80 years treated with recombinant tissue 
plasminogen activator. Materials and Methods: retrospective observational study. We described the main variables and the difference 
in outcome accounting for age. Results: 70 patients were included. 51.4% of the patients were women, 22.8% were older than 80 years. 
The average window time was 70 minutes and the average door-to-needle time was 90 minutes. Hypertension, dyslipidemia and previous 
stroke were the most common risk factors.  Favorable outcome Modified Rankin Scale ≤2 was present in 25% of the patients older than 
80 years and 53.7% in the population younger than 80 years (p=0.009). Mortality was present in 31.2% of the patients older than 80 years 
and in 5.5% of the patients younger than 80 years (p=0.005). Symptomatic intra-cerebral hemorrhage was found in 6.25% of the patients 
older than 80 years (p=0.65), compared to 3.7% in the younger than 80 years. Conclusions: we found that intravenous thrombolysis still 
had benefit in people older than 80 years. Significant differences in symptomatic intra-cerebral hemorrhage were not found, however, a 
greater mortality in patients older than 80 years was.  These findings of our experience of recombinant tissue plasminogen activator use 
in real life are consistent with other latinamerican publications. MÉD.UIS. 2017;30(3):21-30.
Keywords: Stroke. Thrombolytic Therapy. Aged, 80 and over. Risk Factors. Prognosis.
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Estudio observacional sobre tratamiento trombolítico del infarto cerebral agudo en 
pacientes mayores y menores de 80 años: experiencia de un hospital en Bogotá, Colombia, 
2007-2014
RESUMEN
Introducción: describimos la experiencia con el uso de trombólisis para el infarto cerebral isquémico agudo en un centro terciario en 
América del Sur. Objetivos: describir los principales resultados en nuestra población de pacientes menores y mayores de 80 años tratados 
con activador recombinante de plasminógeno tisular. Materiales y Métodos: estudio observacional retrospectivo. Se describieron las 
principales variables y se determinaron los resultados según la edad. Resultados: se incluyeron 70 pacientes. Se encontró que 51,4% eran 
mujeres y 22,8% eran mayores de 80 años. El tiempo de ventana promedio estuvo en 70 minutos, así como el de puerta-aguja de 90 
minutos. La hipertensión, dislipidemia y accidente cerebrovascular previo fueron los factores de riesgo más comunes. En el 25% de los 
pacientes mayores de 80 años y el 53,7% de los menores de 80 años, tuvieron un resultado favorable en la Escala Modificada de Rankin ≤ 2 
(p = 0,009). La mortalidad estuvo presente en el 31,2% de los pacientes mayores de 80 años y en el 5,5% de los pacientes menores de 80 años 
(p = 0,005). La hemorragia intracerebral sintomática fue de 6,25% en los pacientes mayores de 80 años, frente a los menores de 80 años 3,7% 
(p = 0,65). Conclusiones: se encontró que la trombólisis todavía presenta beneficio en personas mayores de 80 años. No se encontraron 
diferencias en cuanto a la hemorragia intra-cerebral sintomática, pero se presentó una mayor mortalidad en los mayores de 80 años. En esta 
experiencia el uso de rt-PA en la vida real es consistente con otras publicaciones latinoamericanas. MÉD.UIS. 2017;30(3):21-30.
Palabras clave: Accidente Cerebrovascular. Terapia Trombolítica. Anciano de 80 o más Años. Factores de Riesgo. Pronóstico.
IntroductIon 
Every year, 15 million people worldwide have a 
stroke. Of those, one-third dies, and one third is left 
with a long-term disability1-3. World mapping has 
shown an increase in the absolute number of people 
having a stroke, demonstrating that the global 
burden of cerebrovascular disease is continually 
increasing with more than 100% increment in stroke 
incidence in developing countries4. 85% of the 
stroken burden worldwide comes from low and 
middle income countries, like Colombia and most of 
the South American Countries5,6. Some investigators 
have predicted an emerging pandemic of non-
communicable chronic conditions like cardiovascular 
disease, including stroke7, mainly due to an ageing 
population.  
In Colombia, South America, life expectancy has 
been growing since 2004. The last data from 2015 
showed that men have a life expectancy of 70.5 years 
and 77.6 years for women with an average of 73.9 
years for the whole country. The projected number 
of people ≥ 80 years of age in 2020 will be 800 885 
compared with 501 077 in 20058. Although there 
is no data available about the incidence of stroke 
in Colombia, it is expected to increase due to the 
ageing population, a phenomenon that has started 
to hit developing countries as well. 
87% of strokes are the result of a vascular occlusion9, 
either because of thrombotic or embolic events that 
lead to vascular blocking and compromised cerebral 
flow. The ischemic event leads to adenosine tri-
phosphate (ATP) deficiency in brain tissue, resulting 
in release of excitatory neurotransmitters and a rise 
of calcium influx, which in turn induce free radicals 
production, ultimately leading to neurotoxicity and 
loss of cell viability10. 
According to the Framingham Heart Study, among 
patients older than 65 years who survived an acute 
stroke and were evaluated six months after the 
event, 50% of them had hemiparesis, 30% needed 
assistance to walk, 19% had aphasia, 35% had 
depressive symptoms and 26% were institutionalized 
in a nursing home. Stroke is the second or third cause 
of death in developing countries, but the first cause 
of disability11. It causes between 0 to 358 disability 
adjusted life years lost calculated for our country5. 
The estimated direct and indirect costs in the United 
States for stroke in 2008 were almost $298 million 
of dollars1. Those results elucidate the diversity of 
disability and dependence1 seen in stroke survivors. 
Thrombolysis improves several outcomes in patients 
with Acute Ischemic Stroke (AIS). Tissue Plasminogen 
Activator (t-PA) acts by enhancing the conversion 
of inactive plasminogen to active plasmin, which 
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in turn causes dissolution and lysis of fibrin clots. 
Recombinant Tissue Plasminogen Activator (rt-PA) 
was designed as a molecule that selectively activates 
fibrin-bound plasminogen12. In 1996, a landmark 
clinical trial demonstrated that intravenous (IV) rt-
PA administered within three hours of the ischemic 
stroke onset improved clinical outcomes at three 
months. Based on the results of this phase III trial, the 
Food and Drug Administration (FDA) approved rt-PA 
for the treatment of AIS13. Furthermore, in 2008 the 
European Cooperative Acute Stroke Study III (ECASS 
III) showed that IV rt-PA given between 3 to 4.5 hours 
after the onset of symptoms significantly improved 
clinical outcomes in patients with AIS14. The results 
of ECASS III led to the extension of the thrombolytic 
window, but patients older than 80 years were 
excluded from participating in the extended window 
time14. Currently, IV thrombolytic therapy is widely 
recommended as the standard of care for AIS in most 
practice guidelines15,16. For every patient admitted in the 
first 3 hours of symptoms onset there is no age limit for 
rt-PA administration (Level of Evidence A, Class I)15.
Safety and efficacy data of rt-PA in the patients 
older than 80 years of age is limited, since they are 
poorly represented in clinical trials due to stringent 
exclusion criteria7. Evidence regarding the benefits 
of rt-PA administration in people < 18 years is scarce; 
moreover, the benefit in people older than 80 
years of age remains controversial, mainly due to 
limitations in the designs of the studies performed in 
this population and the increased risk of intracranial 
bleeding17. 
The European Stroke Organisation (ESO) guidelines 
recommend administering rt-PA to patients over 80 
years of age in selected cases18. The Canadian Stroke 
Best Practice Recommendations guideline advises 
that the decision to treat rests on clinical judgments 
and patient/family wishes19. The Colombian guideline 
encourages the use of rt-PA in patients over 80 years 
old in the extended period (3 hours to 4.5 hours) to 
achieve better outcomes20.
Our aim is to describe the common practice with 
thrombolytic treatment for AIS in the treated 
observed population stratified by age, considering 
younger and older than 80 years in terms of risk 
factors, attention times, complications, disability and 
mortality in the first seven days. Our hypothesis is 
that the patients ≥ 80 years have a worse outcome 
compared with younger counterpart in terms of 
morbidity and mortality in the first week after stroke, 
and obtain less benefit from using rt-PA. We would 
like to show the experience of rt-PA use in Colombia 
because there is a scant amount of publications 
about this important and divisive topic coming from 
our country.
MaterIals and Methods
This is a retrospective observational study developed 
at University Hospital Fundación Santa Fe (UHFS), 
which is a tertiary care center, located in the northeast 
area of Bogotá. The UHFS has a two hundred and five 
beds capacity, and a low rate of stroke admissions of 
approximately 50 to 80 patients a year. The stroke 
center at our Neurology Department implemented 
the main inclusion/exclusion criteria for thrombolysis 
from the National Institutes of Neurological 
Disorders Stroke (NINDS) trial criteria13 and adopted 
the American Heart Association/American Stroke 
Association (AHA/ASA) Guidelines for indications for 
IV rt-PA15. The protocol was submitted and approved 
by the local Institutional Review Board (IRB)/ 
Corporative in Ethics and Research Committee. The 
hospital protocol for thrombolysis takes place in the 
emergency and radiology department during the 
acute phase. We check the inclusion – exclusion criteria 
for thrombolysis and a decision is made whether or 
not to administer the medication or intervention (See 
Figure 1). The stroke code was introduced in 2008 as 
an alert system of the stroke team. 
Figure 1. Acute Stroke Hospital Protocol
ER: Emergency, NIHSS: National Institute of Health Stroke Scale, 
rt-PA: Recombinant Tissue Plasminogen Activator, CT: Computed 
Tomography, MRI: Magnetic Resonance Imaging, I.V: Intravenous
Source: Authors.
All patients admitted to the Neurology Department 
of UHFS between january 2007 and july 2014 were 
identified and included in the study if they met the 
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following inclusion criteria: patients older than 
18 years of age, diagnosed with AIS confirmed by 
neuroimaging, an important measurable neurological 
deficit present, symptom onset in the previous 
4.5 hours and treated with rt-PA, intravenously or 
endovascularly (pharmacological or mechanical), 
if IV rt-PA was contraindicated or considered too 
dangerous. Exclusion criteria were patients who had 
been less than 48 hours in the emergency room and 
subjects with intracranial hemorrhage.   No informed 
consent was necessary in this study due to the less 
than minimum risk for subjects and retrospective 
data review, but removal of patient identifiers was 
performed. We used a standard data collection 
form to retrieve data from the electronic chart of 
each subject. Data collection was performed by the 
investigators in a predefined excel spreadsheet. 
We performed data validation in three different 
opportunities. 
We present baseline characteristics and important 
time periods such as time from onset of symptoms to 
arrival to the emergency room (Window Time), time to 
first neurology encounter, time since admission to rt-
PA administration (Door-to-Needle Time), time from 
admission to neuroimaging studies (Door-to-Image), 
Computed Tomography (CT) or Magnetic Resonance 
Imaging (MRI); the time delay from imaging to image 
interpretation (Door-to-Interpretation), stroke 
severity by National Institute of Health Stroke Scale 
(NIHSS) at admission; complications, mortality, 
length of stay and early outcomes such as the NIHSS 
at discharge and the Modified Rankin Scale (mRS).
Regarding the NIHSS, the neurology resident or senior 
neurologist in charge of the patient determined the 
score on admission, 24 h after rt-PA therapy and at 
discharge or at day seven, whichever happened first. 
A decrease of four or more points in the NIHSS was 
considered clinical improvement; an increase of four 
or more points was considered clinical deterioration. 
Using the clinical findings and diagnostic imaging (CT 
or MRI) obtained on admission and 24 hours after 
symptoms onset (or earlier if clinical deterioration), 
we determined the affected vascular territory and 
the etiology according to the Trial of Org 10 172 
in Acute Stroke Treatment (TOAST)21 scale, after 
completing test evaluation and at discharge. We 
used the definition of Safe Implementation of 
Thrombolysis in Stroke - Monitoring Study (SITS-
MOST) for symptomatic intracerebral hemorrhage 
based on the clinical deterioration of more than four 
NIHSS points from admission or from the lowest 
NIHSS obtained between admission and 24 hours 
and a local or remote parenchymal hematoma type 
2 in the control brain CT at 24 hours22.
statIstIcal analysIs
Data was collected on an electronic spreadsheet 
(Microsoft ® Excel ®, Mac Version 14.4.3 -140616-, 
2011), and then exported to STATA 11.2 (StataCorp ®, 
2009). The baseline characteristics of our population 
were presented using frequencies and proportions 
for categorical variables and central tendency 
measures for continuous variables. Distribution of 
continuous variables was assessed by Shapiro-Wilk 
test of normality. We performed the frequency 
(percentage) of rt-PA use for every one-year period. 
No sample size was calculated due to the descriptive 
nature of the study that analyzed the whole 
population that received rt-PA during the eight-year 
period in UHFS.
The cohort was divided in two groups: < 80 years 
and ≥ 80 years. We evaluated the most important 
prognostic factors as well as clinical and outcome 
variables. We performed Chi-Square or Fischer Test 
for categorical outcomes, Mann and Whitney U test 
for nonparametric analysis of continuous variables 
and the student t-test for variables displaying a 
normal distribution. mRS was dichotimized as 0-2 
and ≥3 and we compared this categorical outcome 
between the two predefined age groups. A statistical 
significance was established with an alpha level of 
<0.05. 
results
A total of 398 subjects had a stroke and attended the 
hospital between 2007 and 2014, of those patients 
17.8% (n=70) received IV rt-PA or endovascular 
intervention. In both 2009 and 2011 we had the 
lowest number of patients, 33, of which 5 patients 
(15.2%) and 9 patients (27.3%), respectively, received 
intervention. The highest number of patients was 74 
in 2014 but only 7 subjects were treated (9,5%) (See 
Graph 1). 
In the selected cohort of 70 patients we found the 
mean age of 69 years with a range of 35 to 97, with 36 
women (51%). The main risk factors were hypertension 
in 75.6% followed by dyslipidemia in 40% and in third 
place previous stroke (38.5%). The stroke code was 
activated in 17% of cases (See Table 1). 
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The most frequent arterial territory affected was 
the left middle cerebral artery in 20 patients (45.5%). 
Timing calculation for the whole cohort showed that 
the patients arrived to the hospital after 78.2 minutes 
with a range of 0 to 257 minutes. The first contact 
with the emergency physician was within 10 minutes 
and with the stroke team in 39 minutes. The lecture 
of the imaging was done in 87.6 minutes and the 
door to needle time was 90 minutes and the onset 
to treatment time was 168 minutes. The NIHSS value at 
admission was 11.7 and at discharge of 7. The mean mRS 
at discharge was 2.2. The mortality was 8.5% (n=6) and 
the length of stay was 10.4 days (See Table 2).
Graph 1. Stroke center thrombolytic experience
AIS: Acute Ischemic Stroke, rt-PA: Recombinant Tissue Plasminogen 
Activator
Source: Authors.
Table 1. Demographic Characteristics
Variable N Mean Range
Risk Factors
Age 70 68.9 35-97
Gender-Female 36 51.4  
Hypertension 53 75.7  
Coronary artery disease 16 22.8  
Diabetes mellitus 10 14.2  
Dislypidemia 28 40  
Atrial Fibrillation 14 20  
Previous stroke 28 38.5  
Stroke Code activation 12 17.1  
Admission Systolic Blood 
Pressure (mmHg)
70 150.5 89-220
Admission Diastolic Blood 
Pressure
70 83 34-120
Vascular Territory
Left-Middle Cerebral Artery 20 45.5  
Right-Middle Cerebral Artery 16 36.3  
Posterior Circulation 6 13.6  
Multiple Territories 1 2.2  
Anterior Cerebral Artery 1 2.2  
Source: Authors.
Table 2. General Times and Scales
Variable N Mean SD Median Range
Window Time (min) 70 78.2 59.7 70 0-257
Time to first 
doctor (min)
70 10 18.3 15.4 0-107
Time to stroke 
team (min)
67 39.1 31.2 33 0-132
Time to imaging 
(min)
63 37.3 30.1 32 1-164
Time to imaging 
lecture (min)
65 87.6 91.9 56 2-479
Door to needle 
time (min)
64 98 44.2 90 22-291
Onset to 
treatment time 
(min)
67 168 66.7 166 58-390
rt-PA dose (mg) 59 55.6 27.7 63 0-90
NIHSS admission 69 11.7 5.5 11 1-25
NIHSS 24 hours 63 7.9 7.9 5 0-42
NIHSS discharge 59 7 8 4 0-42
Discharge mRS 
(7th day)
59 2.2 2 1 0-6
Inhospital mortality 
(7th day)
6 8.5  
Length of stay 
(days)
70 10.4 7.4 8 1-36
rt-PA: recombinant tissue Plasminogen Activator. NIHSS: National 
Institute of Health Stroke Scale. mRS: modified Rankin Scale
Source: Authors.
In our sample we observed 77.2% of the patients < 80 
years old (n=54) and 22.8% patients ≥ 80 years (n=16). 
We found some differences in risk factors between 
both age groups like gender and atrial fibrillation. 
In the older population 75% were females and in 
the younger population 44.4%. Furthermore, in the 
groups of <80 years of age eight patients had atrial 
fibrillation (14.8%), while only six patients (37.5%) had 
it in the >80 years old group (p=0.03) (See Table 3).
MéD.UIS. 2017;30(3):21-30 
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The most common etiology was large vessel disease 
in both groups, 46.3% (n=25) in patients <80 years 
and 56.2% (n=9) in those ≥ 80 years, followed by 
cardioembolic source in 38.9% (n=21) in the younger 
population compared with 37.5% (n=5) in the older 
population (p=0.76). Middle cerebral artery vascular 
territory was the most commonly involved in both 
groups, the left artery within the age <80 years 46.3% 
(n=25), and the right for those patients ≥80 years 
43.7% (n=7), followed by the posterior circulation 
with 12.5% (n=2) in those patients aged ≥ 80 years and 
12.9% (n=7) in the patients <80 years  (p=0.35). 
The time from onset to treatment was less than 180 
minutes in 62% for the patients < 80 years and for 
57.1% in patients ≥ 80 years (p=0.94). The stroke code 
was activated in the 31.2% of patients ≥80 years and 
12.9% in the <80 years (p=0.08). A longer stay was 
observed with a trend between the older population 
with a mean of 13.5 days and 9.5 days for the younger 
population (p=0.07). An improvement of more than 
four points in NIHSS was found in 74% of the patients 
<80 years of age similar to the 75% in the patients ≥80 
years (p=0.94) (See Table 4).
The administration of rt-PA was exclusively IV in 88% 
of the cases (n=62), with two patients that started 
treatment with IV rt-PA followed by endovascular 
treatment (2.86%) and two patients treated with 
rt-PA intraarterially plus IV rt-PA (2.86%). Just four 
subjects had contraindication for IV rt-PA and were 
treated with endovascular devices only (5.71%) 
(p=0.37). 
Table 3. Distributions of risk factors between the observed subjects
 Distribution by age  p value
 < 80 y ≥ 80 y  
% (n) 77.2 (54) 22.8 (16) <0.001
Age range. years 
old
35-80 81-97 <0.001
Gender %. 
female  (n)
44.4 (24)
75 (12)
C7
0.03
Hypertension % 
(n)
72.2 (39) 87.5 (14) 0.21
CAD % (n) 18.5 (10) 37.5 (6) 0.11
Diabetes % (n) 12.9 (7) 18.7 (3) 0.56
Dyslipidemia % (n) 42.5 (23) 31.2 (5) 0.41
AF  % (n) 14.8 (8) 37.5 (6) 0.04
Prior stroke % (n) 40.7 (22) 31.2 (5) 0.49
Weight-Kg 74.2 66.3 0.17
CAD: coronary artery disease AF: Atrial Fibrillation
Source: Authors.
Table 4. Time intervals of attention to thrombolyzed stroke patients 
and outcomes
Time period - minutes Distribution by age  
Mean values < 80 y ≥ 80 y p value
Window Time 76.9 78.6 0.93
Door-to-First doctor 14.2 19.5 0.73
Door-to-Stroke Team  38 43 0.8
Door-to-CT scan 38.1 34.5 0.54
Door-to-Interpretation  88.8 83.5 0.96
Door-to-Needle Time 98.2 97.5 0.64
Stroke Code Activation 
-n(%)
7(31.2) 5(12.9) 0.08
 Main Outcome Stroke Scales
NIHSS admission 10.9 14.1 0.03
NIHSS 24 hours 7.4 9.7 0.34
NIHSS improvement 
-n(%)
40(74) 12 (75) 0.94
NIHSS 7th day 6.5 8.5 0.39
mRS 7th day 1.97 3.1 0.01
Lenght of Stay -days- 9.5 13.5 0.07
CT: Computarized Tomography. NIHSS: National Institute of Health 
Stroke Scale. mRS: modified Rankin Score.
Source: Authors.
In patients ≥ 80 years, we found that 25% of the 
patients had a favorable outcome, with a mRS ≤ 2, 
and 53.7% for those <80 years (p=0.009) (See Graph 
2). 43.7% (n=7) had a mRS between 3 to 5 in the older 
population and 40.7% (n=22) in the younger population 
(p=0.06), with a mortality of 31.2% in patients ≥ 80 years 
compared with 5.5% in patients <80 years (p=0.005). 
We found two symptomatic brain hemorrhages, 
one in the <80-year-old group (3.7%) and one in the 
patients ≥ 80 years (6.25%) (p=0.65).
dIscussIon
In this observational study, we found that in the 
older population patients were more commonly 
women, and atrial fibrillation was more frequent as 
a risk factor. Higher NIHSS at admission and higher 
mortality compared with the younger population was 
also determined. Stroke frequency increases every 
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decade starting at 45 years until 84 years, being more 
frequent in men and after 85 years of age becoming 
more frequent in women23. Atrial fibrillation is an 
important risk factor in the older population, more so 
in women ≥ 80 years. This explains more severe and 
disabling strokes at this age with higher mortality 
and stroke recurrence rates24,25, which correlates 
with our results.
Graph 2. Modified Rankin Scale-Day 7 
Source: Authors.
A good functional prognosis, defined as a mRS 
between zero and two, among subjects ≥ 80 years 
who were treated with rt-PA in the first six hours was 
also found in 27.2% of the treatment group and in 
23.4% of the allocated placebo group (p=0.07)26  in the 
meta - analysis that included the Third International 
Stroke Trial (IST-3) results. Our results showed that 
25% of the older group treated with rt-PA had an 
good functional prognosis at day seven, compared 
with 53.7% in the younger population indicating a 
benefit in both age groups however, clearly larger in 
the patients <80 years27-38. 
Previous reports of other papers have also shown 
that mortality in stroke is related to the annual 
volume of patients. In institutions with medium 
volume as ours39, a similar mortality has been 
reported ranging between 2.4 to 34.8% in a Canadian 
study. Our study shows a mortality range between 
5.5% and 31.2%. This is consistent with the expected 
mortality for our annual volume of patients and for 
the mortality reported in prior trials.
We compared our results with other hospitals in Latin 
America like University Hospital of San Ignacio40 in 
Bogotá and the Hospital de Base do Distrito Federal41 
in Brasilia and the Joinville cohort study in Brazil42, 
however the main information was taken from the 
Hospital de Base do Distrito Federal table paper (See 
Table 5). Our study period was the longest among 
the other published papers; with a larger proportion 
of women and a similar range of NIHSS with the 
hospital last mentioned. The Joinville study included 
patients with NIHSS > ten points due to the design 
of the study, indicating more severe strokes. We 
reported increased improvements of NIHSS > four 
points but with similar disability, measured by mRS ≤ 
two, comparable to the study in University Hospital of 
San Ignacio, but improved compared to the Brazilian 
studies. We believe that gathering this data is an 
important step towards describing the effectiveness 
of rt-PA in this population for South America, which 
includes mainly developing countries. 
Table 5: Comparisons between Hospitals In South America 
regarding rt-PA administration
Characteristics
Study (Hospital/Institution/Region)
UHFS UHSI HBDF Joinville
Number of subjects 70 24 32 82
Study period (years) 8 2 1 2
Mean age (years) 69 NR 59 71.1
Variation (35-97) NR (31-86) NR
Gender (% male) 48 20 59 53.7
NIHSS variation (4-25) (8-20) (3-24) (13.5-21)
Window Time (min) 70 (0-257) NR 118 (11-228) 77
Door to needle time 
(min)
90 (22-291) NR 89 (32-244) NR
Onset to treatment 
(min)
166 (58-390) NR 195 (60-270) 170
Significant 
improvement in NIHSS 
(%)
50 NR 50 NR
Favourable result at 
discharge (mRS 0-2) 
(%)
55 50 44 37
Hemorrhagic 
transformation  (%)
4 NR 6 12
Mortality (%) 9 12 13 39
UHFS:University Hospital Fundacion Santa Fe, UHSI: University 
hospital of San Ignacio
HBDF:Hospital de Base do Distrito Federal
rt-PA:recombinant tissue Plasminogen Activator. NIHSS: National 
Institute of Health Stroke Scale. mRS: modified Rankin Score. NR: 
non-reported
Source: Authors.
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Thereby we decided to compare our results with 
similar non-randomized controlled studies as 
shown27-37. They compared treated patients older 
and younger than 80 years, with better disability 
outcomes measured by mRS in the youngest 
population, with no striking difference in symptomatic 
intracerebral hemorrhage, but with a remarkable 
intra-hospital mortality and at three months (See 
Table 6). These results were also corroborated by 
a meta-analysis that showed a combined OR for 
symptomatic intracerebral hemorrhage of 1.27 [CI 
95%, 0.85 to 1.91] (ns), mortality at three months 
OR=3.18 [CI 95%, 2.48 to 4.09] and mRS OR=0.52 
[CI 95% 0.42 to 0.64] for better outcome for the 
youngest35. They presented as a possible explanation 
for increasing mortality in the older population more 
severe deficits at presentation7, as in our cohort of 
≥ 80 years with an average of admission NIHSS of 
14 points compared with 11 points in the < 80 years. 
Severity could also be explained by the number 
of associated comorbidities in the octogenarian 
population as described previously43.
Table 6: Data extraction of observational studies of thrombolysis in older and younger than 80 years
Study (year) n Age mRS ≤ 1 OR mRS ≤ 2 OR SICH Mortality
  
<80 >80 <80 >80
 
<80 >80
 
<80 >80 <80 >80
Van 
Oostenbrugge 
(2006)27
184 139(76) 45(24) 45% 27% 2.2 [1.0-4.0] 63% 36% 3.13[1.5-6.3] 2.9% 11.1% 16.0% 40.0%
Tanne (2000)*28 189 159(84) 30(16) 30% 37% 1.3[0.5-3.6] 62% 54% ns 6.0% 3.0% 8.0% 20.0%
Uyttenboogaart 
(2007)29
142 111(78) 31(22) 36.1% 16.1% ns ns ns 2.6[0.8-8.7] 3.6% 9.7% 10.8% 12.9%
Boulouis (2012)30 400 302(75) 98(25) ns ns ns 70% 52% 0.5[0.3-0.8] 10.0% 12.0% 6.0% 10.0%
Gómez - Chocó 
(2008)31
157 108(68) 49(32) 37%† 25%† ns ns ns ns 6.0% 6.0% 10.0% 6.0%
Toni (2008)32 248 207(83) 41(17) ns ns ns 58.5% 44.0% ns 2.4% 2.4% 10.6% 34.1%
Berrouschot 
(2005)33
228 190(84) 38(16) 46.8% 26.3% ns 61.6% 31.6% ns 2.6% 2.6% 5.3% 21.1%
Chen (2005)34 183 127(69) 56(31) ns ns ns ns ns ns 6.3% 7.1% 11.0% 20.0%
Ringleb (2005)¥35 478 378(79) 90(21) 44.8%ꜛ 20.3%ꜛ ns ns ns ns 5.3% 6.9% 14%ꜛ 29.7%ꜛ
Sylaja (2006)36 1135 865(76) 270(24) 40% 26% ns 66.6% 44.7% ns 4.6% 4.4% 18.2% 35.3%
Meseguer 
(2008)37
129 107(83) 22(17) 37% 27% ns ns ns ns 7.5% 13.6% 11.2% 27.3%
Mouradian 
(2005)38
96 65(67) 31(23) ns ns ns 58.5% 16.1% 0.14[.05-0.4] 6.2% 9.7% 9.2% 32.3%
Bayona (2017) 70 54(77) 16(13) ns ns ns 53.7% 25.0%  2.8[.75-10.4]¶ 3.7% 6.2% 5.5% 31.2%
ns:not specified. mRS:modified Rankin Scale. OR: Odds Ratio SICH:Symptomatic Intracerebral Hemorrhage
*Multicenter study
† mRS<1 if basal mRS≤2
ꜛPatients selected by CT
¥ Data from study and also meta-analysis from previous studies
¶Post-hoc analysis 
Source: Authors.
To the best of our knowledge this is probably the first 
English report of thrombolytic therapy in our country 
and also is the largest series of rt-PA use published 
in Colombia. Data showed a low annual volume of 
patients between 2007 and 2014, with an average 
number of nine patients every year that were 
treated with rt-PA, meaning that 17.6% of the patients 
benefited from rt-PA treatment. Our study showed 
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almost triple the average use of thrombolysis in 
AIS patients than in the United States, 3.4% to 5.2%, 
reflecting the characteristics of our center44. UHFS 
is a tertiary center with a Stroke Unit and stroke 
code. It has been described that having an alert 
system, significantly reduces the time to neurology 
staff assessment, time to CT scan, time to laboratory 
testing and door to needle time, and that increases 
the rate of rt-PA administration45. 
lIMItatIons
Due to the study design and sample size, we expect 
this study could be basal data generated in the 
stroke field that is limited in our country and in South 
America. Although our study involves a small cohort 
it shows data for a longer time period (eight years) as 
compared to other previous published data in South 
America. Unfortunately, we did not include a crucial 
outcome variable such as the place of discharge 
of the subjects because this varies consistently in 
different age strata as shown in previous studies43. 
We also missed in the study design the combination 
and severity of different conditions that worsen the 
prognosis in this advanced age population.
We are also aware that our center’s characteristics 
are not generalizable of the vast majority of the 
hospitals in our country. We expect that a high 
population of patients live in areas with low access 
to health care and few hospitals have the training 
and resources to administer rt-PA. Therefore, we 
presume that other hospitals in our country might 
have lower rt-PA utilization rates and perhaps worst 
functional outcomes and higher mortality rates. 
conclusIons and recoMMendatIons
Despite the lack of a randomized controlled trial in 
this age range population, our study suggests that 
thrombolysis still has a beneficial effect in patients 
older than 80 years, when they are compared with 
patients younger than 80 years in terms of disability 
at discharge. We found that mortality is higher at 
seven days in the older population, probably due 
to factors related to stroke, patient fragility and 
comorbidities. Although a small sample size this 
study serves as a stepping-stone in understanding 
and better characterizing our population in regards 
to rt-PA use and benefits especially that is poorly 
studied in population older than 80 years. Given 
the scarcity of evidence in our country we strongly 
believe that patients and families should be advised 
and informed about the goals of therapy, potential 
complications and realistic outcomes. 
ethIc consIderatIons
The study was approved by the Institutional Review 
Board (IRB)/ Corporative in Ethics and Research 
Committee of the University Hospital Fundación 
Santa Fe de Bogotá.
source of fundIng
None.
conflIct of Interest
The authors declare that there is no conflict of 
interest.
acknowledgeMents 
To the radiology department and the department of 
clinical studies Fundación Santa Fe de Bogotá, Elisa 
Margarita Sánchez, Nicolle Vargas, Sergio Prieto, and 
Natalia Ramírez.
references 
1. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden 
WB, et al. Heart disease and stroke statistics-2012 update: a 
report from the American Heart Association. Circulation. 
2012;125(1):2-220.
2. Wechsler LR. Intravenous Thrombolytic Therapy for Acute 
Ischemic Stroke. N Engl J Med. 2011;364(22):2138-46.
3. World Health Organization [Internet]. Global burden of stroke 
[Citado 2016 Dic 18]. Disponible en: http://www.who.int/
cardiovascular_diseases/en/cvd_atlas_15_burden_stroke.
pdf?ua=1]. 
4. Feigin VL, Lawes CM, Bennett DA, Barker-Collo SL, Parag V. 
Worldwide stroke incidence and early case fatality reported in 
56 population-based studies: a systematic review. Lancet Neurol. 
2009;8(4):355-69.
5. Feigin VL, Mensah GA, Norrving B, Murray CJ, Roth GA. Atlas of 
the Global Burden of Stroke (1990-2013): The GBD 2013 Study. 
Neuroepidemiology. 2015;45(3):230-6.
6. Johnston SC, Mendis S, Mathers CD. Global variation in stroke 
burden and mortality: estimates from monitoring, surveillance, 
and modelling. Lancet Neurol. 2009;8(4):345-54.
7. Saposnik G, Cote R, Phillips S, Gubitz G, Bayer N, Minuk J, et 
al. Stroke outcome in those over 80: a multicenter cohort study 
across Canada. Stroke. 2008;39(8):2310-7.
8. DANE [internet]. Population and Demography - Projected 
Populations. [Citado 2017 Ene 30]. Available from: http://www.
dane.gov.co/index.php/estadisticas-por-tema/demografia-y-
poblacion/proyecciones-de-poblacion.
9. Van der Worp HB, van Gijn J. Clinical practice. Acute ischemic 
stroke. N Engl J Med. 2007;357(6):572-9.
10. Lo EH, Dalkara T, Moskowitz MA. Mechanisms, challenges and 
opportunities in stroke. Nat Rev Neurosci. 2003;4(5):399-415.
11. Strong K, Mathers C, Bonita R. Preventing stroke: saving lives 
MéD.UIS. 2017;30(3):21-30 
30
Bayona-Ortíz H, Díaz-Cruz CA, Góez-Mogollón L, Useche-Gómez N, Valencia-Mendoza MC, López VJ, et  al.
around the world. Lancet Neurol. 2007;6(2):182-7.
12. Del Zoppo GJ. Plasminogen activators and ischemic stroke: 
conditions for acute delivery. Semin Thromb Hemost. 
2013;39(4):406-25.
13. The National Institute of Neurological Disorders and Stroke rt-
PA Stroke Study Group. Tissue Plasminogen Activator for Acute 
Ischemic Stroke. New Engl J Med. 1995;333(24):1581-8.
14. Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti 
D, et al. Thrombolysis with Alteplase 3 to 4.5 hours after Acute 
Ischemic Stroke. N Engl J Med. 2008;359(13):1317-29.
15. Jauch EC, Saver JL, Adams HP, Bruno A, Connors JJ, Demaerschalk 
BM, et al; American Heart Association Stroke Council; Council 
on Cardiovascular Nursing; Council on Peripheral Vascular 
Disease; Council on Clinical Cardiology. Guidelines for the early 
management of patients with acute ischemic stroke: a guideline 
for healthcare professionals from the American Heart Association/
American Stroke Association. Stroke. 2013;44(3):870-947.
16. Coutts SB, Wein TH, Lindsay MP, Buck B, Cote R, Ellis P, et al; 
Heart, and Stroke Foundation Canada Canadian Stroke Best 
Practices Advisory Committee. Canadian Stroke Best Practice 
Recommendations: secondary prevention of stroke guidelines, 
update 2014. Int J Stroke. 2015;10(3):282-91.
17. Demaerschalk BM, Kleindorfer DO, Adeoye OM, Demchuk AM, 
Fugate JE, Grotta JC, et al; American Heart Association Stroke 
Council and Council on Epidemiology and Prevention. Scientific 
Rationale for the Inclusion and Exclusion Criteria for Intravenous 
Alteplase in Acute Ischemic Stroke. A Statement for Healthcare 
Professionals From the American Heart Association/American 
Stroke Association. Stroke. 2016;47(2):581-641.
18. European Stroke Organisation. Guidelines for management 
of ischaemic stroke and transient ischaemic attack 2008. 
Cerebrovasc Dis. 2008;25(5):457-507.
19. Lindsay P, Bayley M, Hellings C, Hill M, Woodbury E, Phillips S. 
Canadian best practice recommendations for stroke care (updated 
2008). CMAJ. 2008;179(12 Suppl):S1-25.
20. Colombian General Social Security System for Health. Clinical 
Practice Guideline for diagnosis, treatment and rehabilitation of 
Acute Ischemic Stroke in population over the age of 18. 2015.
21. Adams HJ, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon 
DL, et al. Classification of subtype of acute ischemic stroke. 
Definitions for use in a multicenter clinical trial. TOAST. Trial of 
Org 10172 in Acute Stroke Treatment. Stroke. 1993;24(1):35-41.
22. Wahlgren N, Ahmed N, Dávalos A, Ford GA, Grond M, Hacke 
W, et al. Thrombolysis with alteplase for acute ischaemic 
stroke in the Safe Implementation of Thrombolysis in Stroke-
Monitoring Study (SITS-MOST): an observational study. Lancet. 
2007;369(9558):275-82.
23.      Petrea RE, Beiser AS, Seshadri S, Kelly-Hayes M, Kase CS, Wolf PA. 
Gender Differences in Stroke Incidence and Poststroke Disability 
in the Framingham Heart Study. Stroke. 2009;40(4):1032-7.
24. Marini C, De Santis F, Sacco S, Russo T, Olivieri L, Totaro R, et al. 
Contribution of Atrial Fibrillation to Incidence and Outcome of 
Ischemic Stroke: Results From a Population-based Study. Stroke. 
2005;36(6):1115-9.
25. Bushnell C, McCullough LD, Awad IA, Chireau MV, Fedder WN, 
Furie KL, et al. Guidelines for the prevention of stroke in women: 
a statement for healthcare professionals from the American 
Heart Association/American Stroke Association. Stroke. 
2014;45(5):1545-88.
26. Wardlaw JM, Murray V, Berge E, del Zoppo G, Sandercock P, 
Lindley RL, et al. Recombinant tissue plasminogen activator for 
acute ischaemic stroke: an updated systematic review and meta-
analysis. Lancet. 2012;379(9834):2364-72.
27. van Oostenbrugge RJ, Hupperts RM, Lodder J. Thrombolysis for 
acute stroke with special emphasis on the very old: experience 
from a single Dutch centre. J Neurol Neurosurg Psychiatry. 
2006;77(3):375-7.
28. Tanne D, Gorman MJ, Bates VE, Kasner SE, Scott P, Verro P, et al. 
Intravenous tissue plasminogen activator for acute ischemic 
stroke in patients aged 80 years and older : the tPA stroke survey 
experience. Stroke. 2000;31(2):370-5.
29.  Uyttenboogaart M, Schrijvers EM, Vroomen PC, De Keyser J, 
Luijckx GJ. Routine thrombolysis with intravenous tissue 
plasminogen activator in acute ischaemic stroke patients aged 
80 years or older: a single centre experience. Age and ageing. 
2007;36(5):577-9. 
30. Boulouis G, Dumont F, Cordonnier C, Bodenant M, Leys D, Henon 
H. Intravenous thrombolysis for acute cerebral ischaemia in old 
stroke patients >/= 80 years of age. J Neurol. 2012;259(7):1461-7.
31. Gomez-Choco M, Obach V, Urra X, Amaro S, Cervera A, Vargas 
M, et al. The response to IV rt-PA in very old stroke patients. Eur 
J Neurol. 2008;15(3):253-6.
32. Toni D, Lorenzano S, Agnelli G, Guidetti D, Orlandi G, Semplicini 
A, et al. Intravenous thrombolysis with rt-PA in acute ischemic 
stroke patients aged older than 80 years in Italy. Cerebrovasc Dis. 
2008;25(1-2):129-35.
33. Berrouschot J, Rother J, Glahn J, Kucinski T, Fiehler J, Thomalla G. 
Outcome and severe hemorrhagic complications of intravenous 
thrombolysis with tissue plasminogen activator in very old (> or 
=80 years) stroke patients. Stroke. 2005;36(11):2421-5.
34. Chen CI, Iguchi Y, Grotta JC, Garami Z, Uchino K, Shaltoni H, 
et al. Intravenous TPA for very old stroke patients. Eur Neurol. 
2005;54(3):140-4.
35. Ringleb PA, Schwark C, Kohrmann M, Kulkens S, Juttler E, 
Hacke W, et al. Thrombolytic therapy for acute ischaemic stroke 
in octogenarians: selection by magnetic resonance imaging 
improves safety but does not improve outcome. J Neurol 
Neurosurg Psychiatry. 2007;78(7):690-3.
36. Sylaja PN, Cote R, Buchan AM, Hill MD. Thrombolysis in patients 
older than 80 years with acute ischaemic stroke: Canadian 
Alteplase for Stroke Effectiveness Study. J Neurol Neurosurg 
Psychiatry. 2006;77(7):826-9.
37. Meseguer E, Labreuche J, Olivot JM, Abboud H, Lavallee 
PC, Simon O, et al. Determinants of outcome and safety of 
intravenous rt-PA therapy in the very old: a clinical registry study 
and systematic review. Age Ageing. 2008;37(1):107-11.
38. Mouradian MS, Senthilselvan A, Jickling G, McCombe JA, Emery 
DJ, Dean N, et al. Intravenous rt-PA for acute stroke: comparing its 
effectiveness in younger and older patients. J Neurol Neurosurg 
Psychiatry. 2005;76(9):1234-7.
39. Saposnik G, Baibergenova A, O’Donnell M, Hill MD, Kapral MK, 
Hachinski V, et al. Hospital volume and stroke outcome: Does it 
matter?. Neurology. 2007;69(11):1142-51.
40. Castañeda Cardona C, Coral Casas J, Rueda MC, Díaz Cortés D, 
Ruíz A. Experience with intravenous thrombolysis for stroke 
in the Hospital Universitario San Ignacio 2011-2013 (EXTRO 
HUSI). Acta Neurol Colomb. 2014;30(1):16-21.
41. Tosta ED, Rebello LC, Almeida SS, Neiva MS. Treatment of 
ischemic stroke with r-tPA: implementation challenges in a tertiary 
hospital in Brazil. Arq Neuropsiquiatr. 2014;72(5):368-72.
42.     Cabral NL, Conforto A, Magalhaes PS, Longo AL, Moro CH, Appel 
H, et al. Intravenous rtPA versus mechanical thrombectomy in 
acute ischemic stroke: A historical cohort in Joinville, Brazil. 
eNeurologicalSci. 2016;5:1-6.
43. Arora R, Salamon E, Katz JM, Cox M, Saver JL, Bhatt DL, et al. Use 
and Outcomes of Intravenous Thrombolysis for Acute Ischemic 
Stroke in Patients ≥90 Years of Age. Stroke. 2016;47:2347-54.
44. Adeoye O, Hornung R, Khatri P, Kleindorfer D. Recombinant 
tissue-type plasminogen activator use for ischemic stroke in the 
United States: a doubling of treatment rates over the course of 5 
years. Stroke. 2011;42(7):1952-5.
45. Heo JH, Kim YD, Nam HS, Hong K-s, Ahn SH, Cho HJ, et al. A 
Computerized In-Hospital Alert System for Thrombolysis in 
Acute Stroke. Stroke. 2010;41:1978-83.
